Investors are Bullish on Optimer's Fidaxomicin
Excitement is building in advance of an FDA advisory committee meeting on Tuesday to review fidaxomicin, an antibiotic candidate being developed by Optimer Pharmaceuticals Inc. for Clostridium difficile infection (CDI).